Robert Lustig on GLP-1 Drugs: warns against

Dr. Robert Lustig warns against treating GLP-1 drugs (Ozempic, Wegovy) as the solution to metabolic disease. In a September 2026 interview — with chapters titled “Robert Lustig On Ozempic, Wegovy & GLP-1 Drugs,” “The Potential Downsides Of GLP-1s,” and “Why Robert Says We Still Have To Fix The Food” — he argues that these drugs treat the symptom while the food supply remains broken.

His stated reasoning is that pharmaceutical intervention does not address the upstream cause he attributes to chronic disease: a food environment built on added sugar and ultra-processed products. As with all his positions, this is Lustig’s stated view, not medical advice.

This page chronicles a stated position of the person above. It is not medical advice and not the site's own conclusion.